Home

Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)

1.0501
-0.0399 (-3.66%)

Enlivex Therapeutics Ltd is a biotechnology company focused on developing innovative therapies to harness the body’s immune system to treat a range of serious conditions

The company specializes in the research and development of cell therapy products aimed at modulating the immune response, particularly in the context of autoimmune diseases and other severe health conditions. With a commitment to advancing novel treatments, Enlivex aims to improve patient outcomes through its cutting-edge technological approaches and potential game-changing medical solutions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Via Benzinga · April 29, 2024
Tesla To $180? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · April 12, 2024
Nasdaq Jumps 250 Points; Crude Oil Down 1%benzinga.com
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26.
Via Benzinga · April 11, 2024
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionbenzinga.com
Shares of Fastenal Company (NASDAQFAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via Benzinga · April 11, 2024
Dow Dips 100 Points; CarMax Earnings Miss Viewsbenzinga.com
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.
Via Benzinga · April 11, 2024
Nasdaq Gains Over 50 Points; US Producer Prices Increase In Marchbenzinga.com
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94. The S&P 500 also rose, gaining, 0.17% to 5,169.21.
Via Benzinga · April 11, 2024
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023investorplace.com
ENLV stock results show that Enlivex Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 5, 2024
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Shares of RayzeBio, Inc. (NASDAQRYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday.
Via Benzinga · December 26, 2023
This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancerbenzinga.com
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQENLV) was recently a guest on Benzinga’s All-Access.
Via Benzinga · June 16, 2023
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Shares of AAR Corp. (NYSEAIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via Benzinga · December 22, 2023
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trialsbenzinga.com
This month, H.C. Wainwright & Co.
Via Benzinga · April 13, 2023
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Gainers Benson Hill, Inc. (NYSEBHIL) shares jumped 48.1% to $0.3740.
Via Benzinga · November 3, 2023
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumorsbenzinga.com
This month, Enlivex Therapeutics Ltd.
Via Benzinga · April 11, 2023
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarketbenzinga.com
Gainers PLx Pharma Inc. (NASDAQPLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday.
Via Benzinga · April 10, 2023
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
By Rachael Green, Benzinga
Via News Direct · December 7, 2022
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga
Via News Direct · December 6, 2022
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga
Via News Direct · December 2, 2022
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
By Rachael Green, Benzinga
Via News Direct · December 1, 2022
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignanciesbenzinga.com
Enlivex Therapeutics Ltd. (NASDAQENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an  Investigational New Drug (IND) application to study Allocetra™ in patients with advanced solid malignancies.
Via Benzinga · November 29, 2022
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTMbenzinga.com
On November 13, Enlivex (NASDAQENLV) announced that the first patient has been dose
Via Benzinga · November 22, 2022
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatmentbenzinga.com
Enlivex Therapeutics Ltd.
Via Benzinga · November 15, 2022
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatmentbenzinga.com
Sign up for this week’s All Access giveaway here! 
Via Benzinga · November 15, 2022
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trialbenzinga.com
Enlivex Therapeutics Ltd. (NASDAQENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga · November 1, 2022
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answersbenzinga.com
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via Benzinga · October 25, 2022
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumorsbenzinga.com
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQENLV) proprietary immunothera
Via Benzinga · October 6, 2022